RT Journal Article
SR Electronic
T1 Calcium-sensing receptor antagonism as a novel therapeutic for pulmonary fibrosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.12.20034751
DO 10.1101/2020.03.12.20034751
A1 Kasope L. Wolffs
A1 Bethan Mansfield
A1 Richard T. Bruce
A1 Ping Huang
A1 Martin Schepelmann
A1 Sarah C Brennan
A1 Line Verckist
A1 Dirk Adriaensen
A1 Rachel Paes De Araújo
A1 Luis A.J. Mur
A1 Richard Attanoos
A1 Keir E. Lewis
A1 Jeremy P.T. Ward
A1 Christopher J. Corrigan
A1 Paul J. Kemp
A1 Benjamin D. Hope-Gill
A1 Daniela Riccardi
YR 2020
UL http://medrxiv.org/content/early/2020/03/16/2020.03.12.20034751.abstract
AB Background Idiopathic pulmonary fibrosis (IPF) is a disease with very poor prognosis and no curative therapies. The G protein-coupled, calcium/cation-sensing receptor (CaSR) is activated by environmental pollutants and by arginine-derived polyamines, which are thought to play a role in IPF. Whether the CaSR is involved in the pathogenesis of pulmonary fibrosis is unknown.Objective To investigate the CaSR as a novel drug target for the treatment of pulmonary fibrosis (PF).Methods and results CaSR protein expression is found in the airway epithelium in the neuroepithelial bodies of the healthy and IPF human lung. Expression of arginine pathway-linked polyamines is increased in PF patient saliva samples compared to non-PF patients. Arginine pathway metabolites, ornithine and spermine, activate the CaSR in primary normal human lung fibroblasts (NHLF), effects prevented by CaSR antagonism using the calcilytic NPS2143. In NHLF calcilytic also reversed the pro-fibrotic effects of exogenous TGFβ1 administration on Rho kinase and αSMA expression, proliferation, collagen production and IL-8 secretion. Targeted CaSR ablation from fibroblasts and smooth muscle cells protects mice from spontaneously occurring, age-related lung fibrosis.Conclusions Sustained CaSR activation in the lung drives pro-fibrotic processes, which can be reversed by calcilytic. Pharmacological and genetic CaSR blockade reduce both TGFβ1-induced and naturally occurring pro-fibrotic changes. This work provides the scientific rationale for developing inhaled calcilytics as novel therapeutics for IPF.Key question How does the calcium/cation-sensing receptor (CaSR) promote pulmonary fibrosis?Bottom line The CaSR is expressed in human IPF and experimental models of PF where receptor inhibition prevents pro-fibrotic changes and pulmonary remodeling.Why read on CaSR blockers, calcilytics, represent a novel treatment for IPF.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors wish to thank the financial support of the King’s Commercialization Institute (to DR), the Saunders Legacy Lung Research (to BHG and DR), and the Marie Curie ETN “Multifaceted CaSR” (to PJK and DR). No author has received payment or services from third party for any aspect of the submitted work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article or uploaded as supplementary information